HK1253572A1 - 作為tnap抑制劑的吡啶並噁嗪酮化合物 - Google Patents

作為tnap抑制劑的吡啶並噁嗪酮化合物

Info

Publication number
HK1253572A1
HK1253572A1 HK18112777.4A HK18112777A HK1253572A1 HK 1253572 A1 HK1253572 A1 HK 1253572A1 HK 18112777 A HK18112777 A HK 18112777A HK 1253572 A1 HK1253572 A1 HK 1253572A1
Authority
HK
Hong Kong
Prior art keywords
pyrido
tnap inhibitors
oxazinone derivatives
oxazinone
derivatives
Prior art date
Application number
HK18112777.4A
Other languages
English (en)
Inventor
Shojiro Miyazaki
Yuko Yamamoto
Keisuke Suzuki
Masaharu Inui
Masanori Izumi
Kaori Soma
Anthony Pinkerton
Taeko Shinozaki
Original Assignee
Daiichi Sankyo Co Ltd
Sanford Burnham Prebys Medical Discovery Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd, Sanford Burnham Prebys Medical Discovery Inst filed Critical Daiichi Sankyo Co Ltd
Publication of HK1253572A1 publication Critical patent/HK1253572A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
HK18112777.4A 2015-07-08 2018-10-08 作為tnap抑制劑的吡啶並噁嗪酮化合物 HK1253572A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562190145P 2015-07-08 2015-07-08

Publications (1)

Publication Number Publication Date
HK1253572A1 true HK1253572A1 (zh) 2019-06-21

Family

ID=57045381

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18112777.4A HK1253572A1 (zh) 2015-07-08 2018-10-08 作為tnap抑制劑的吡啶並噁嗪酮化合物

Country Status (30)

Country Link
US (3) US9920068B2 (zh)
EP (1) EP3319970B1 (zh)
JP (1) JP6666928B2 (zh)
KR (1) KR102590067B1 (zh)
CN (1) CN107207527B (zh)
AU (1) AU2016291163B2 (zh)
BR (1) BR112017006798A2 (zh)
CA (1) CA2962795C (zh)
CO (1) CO2017003830A2 (zh)
CY (1) CY1122477T1 (zh)
DK (1) DK3319970T3 (zh)
ES (1) ES2754480T3 (zh)
HK (1) HK1253572A1 (zh)
HR (1) HRP20192121T1 (zh)
HU (1) HUE046994T2 (zh)
IL (1) IL251005B (zh)
LT (1) LT3319970T (zh)
MX (1) MX2017003822A (zh)
MY (1) MY185558A (zh)
NZ (1) NZ729387A (zh)
PH (1) PH12018500066A1 (zh)
PL (1) PL3319970T3 (zh)
PT (1) PT3319970T (zh)
RS (1) RS59594B1 (zh)
RU (1) RU2715704C2 (zh)
SG (1) SG11201701378WA (zh)
SI (1) SI3319970T1 (zh)
TW (1) TWI702220B (zh)
WO (1) WO2017007943A1 (zh)
ZA (1) ZA201701783B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119449A1 (en) * 2016-12-23 2018-06-28 Daiichi Sankyo Company, Limited Oxazepine derivatives having tnap inhibitory activity
JP7005629B2 (ja) * 2016-12-23 2022-01-21 第一三共株式会社 Ｔｎａｐ阻害活性を有するスルホンアミド化合物
CN112912139A (zh) 2018-10-23 2021-06-04 第一三共株式会社 联芳基衍生物
CN114085911B (zh) * 2022-01-19 2022-05-17 珠海圣美生物诊断技术有限公司 一种检测肿瘤细胞或肿瘤细胞碎片的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810795A (en) 1982-09-30 1989-03-07 A. H. Robins Company, Incorporated Certain 2,5 and 2,5,6-di- and tri-substituted nicotinic acid intermediates
AU1409100A (en) 1998-11-27 2000-06-19 Takeda Chemical Industries Ltd. Drugs
PE20011061A1 (es) * 2000-02-01 2001-11-20 Procter & Gamble Cristalizacion selectiva del acido 3-piridil-1-hidroxi-etiliden-1,1-bisfosfonico sodio como el hemipentahidrato o el monohidrato
WO2007007040A1 (en) 2005-07-09 2007-01-18 Astrazeneca Ab 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
EP2433496A1 (en) 2007-05-08 2012-03-28 Burnham Institute for Medical Research Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
KR102083041B1 (ko) * 2012-02-22 2020-05-27 샌포드 번햄 프레비즈 메디컬 디스커버리 인스티튜트 술폰아미드 화합물 및 ｔｎａｐ 억제제로서 용도

Also Published As

Publication number Publication date
PH12018500066A1 (en) 2018-07-09
AU2016291163A1 (en) 2017-03-16
ES2754480T3 (es) 2020-04-17
EP3319970B1 (en) 2019-08-28
NZ729387A (en) 2023-12-22
US9879032B2 (en) 2018-01-30
ZA201701783B (en) 2018-12-19
WO2017007943A1 (en) 2017-01-12
RU2017117179A3 (zh) 2019-09-24
IL251005A0 (en) 2017-04-30
AU2016291163B2 (en) 2020-01-23
US9920068B2 (en) 2018-03-20
KR102590067B1 (ko) 2023-10-16
RU2715704C2 (ru) 2020-03-03
HUE046994T2 (hu) 2020-04-28
TWI702220B (zh) 2020-08-21
PL3319970T3 (pl) 2020-03-31
CA2962795C (en) 2019-09-10
JP6666928B2 (ja) 2020-03-18
CY1122477T1 (el) 2021-01-27
KR20180028395A (ko) 2018-03-16
US20170240562A1 (en) 2017-08-24
JP2018522814A (ja) 2018-08-16
TW201713668A (zh) 2017-04-16
CN107207527B (zh) 2019-10-01
LT3319970T (lt) 2019-11-11
RU2017117179A (ru) 2019-08-08
DK3319970T3 (da) 2019-12-02
CA2962795A1 (en) 2017-01-12
SI3319970T1 (sl) 2019-12-31
BR112017006798A2 (pt) 2018-01-09
US10221195B2 (en) 2019-03-05
EP3319970A1 (en) 2018-05-16
HRP20192121T1 (hr) 2020-02-21
RS59594B1 (sr) 2020-01-31
IL251005B (en) 2020-03-31
US20180141960A1 (en) 2018-05-24
US20170210755A1 (en) 2017-07-27
MX2017003822A (es) 2017-06-26
SG11201701378WA (en) 2018-01-30
CN107207527A (zh) 2017-09-26
PT3319970T (pt) 2019-11-15
MY185558A (en) 2021-05-20
CO2017003830A2 (es) 2017-08-31

Similar Documents

Publication Publication Date Title
IL278916A (en) Benzoimidazole derivatives as PAD4 inhibitors
SI3371190T1 (sl) Heterociklične spojine kot inhibitorji PI3K gama
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
HK1255269A1 (zh) 作為parp抑制劑的雜芳基衍生物
HK1226398A1 (zh) 作為midh1抑制劑的苯並咪唑-2-胺
HK1251566A1 (zh) 作為hdac1/2抑制劑的呱啶衍生物
HRP20190127T1 (hr) Derivati pirolidinona kao inhibitori metap-2
IL246345A0 (en) History of 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid as neprilysin inhibitors
HK1232227A1 (zh) 作為 抑制劑的喹嗪酮衍生物
HK1253572A1 (zh) 作為tnap抑制劑的吡啶並噁嗪酮化合物
HK1251572A1 (zh) 作為ddr1抑制劑的三氮雜-螺癸酮類化合物
IL252866B (en) History of imidazopyridazine as pi3k beta inhibitors
HK1252767A1 (zh) 作為eaat3抑制劑的吡唑-吡啶衍生物